Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|April 30, 2025
[Efforts to develop therapeutic agents for bacterial infections to fight against AMR (antimicrobial resistance)]Miki Takemura
The Journal of Antimicrobial Chemotherapy|March 15, 2022
Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testingErika Matuschek, Christopher Longshaw, Miki Takemura, et al.
Antimicrobial Agents and Chemotherapy|August 23, 2023
In vitro efficacy of humanized regimen of flomoxef against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniaeHidenori Yamashiro, Yu Kasamatsu, Naomi Anan, et al.
ACS Applied Bio Materials|March 18, 2025
Siglec-14-Mediated Inflammatory Responses to Carbon NanomaterialsShin-Ichiro Yamaguchi, Miki Takemura, Karen Miwa, et al.
The Journal of Antimicrobial Chemotherapy|June 30, 2023
In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019)Miki Takemura, Mark G Wise, Meredith A Hackel, et al.
Journal of Global Antimicrobial Resistance|December 27, 2021
Characterisation of cefiderocol-non-susceptible Acinetobacter baumannii isolates from TaiwanYoshinori Yamano, Naoki Ishibashi, Miho Kuroiwa, et al.
Antimicrobial Agents and Chemotherapy|November 22, 2021
In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019James A Karlowsky, Meredith A Hackel, Miki Takemura, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|January 25, 2022
Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical TrialsPatrice Nordmann, Ryan K Shields, Yohei Doi, et al.
The Journal of Antimicrobial Chemotherapy|February 13, 2023
In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumanniiChristian M Gill, Debora Santini, Miki Takemura, et al.
Antimicrobial Agents and Chemotherapy|November 16, 2023
In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolatesMiki Takemura, Rio Nakamura, Merime Ota, et al.
Pageof 3